+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the drug LXE408 in people with chronic Chagas disease who do not have severe organ dysfunction. This phase 2, randomized, participant- and investigator-blinded study compares LXE408 to placebo and the standard treatment benznidazole. The goal is to assess the drugs ability to clear or reduce parasites in the blood, as well as its safety, tolerability, pharmacokinetics, and pharmacodynamics. Participants are assigned to one of four groups LXE408 for 28 days, LXE408 for 14 days followed by placebo for 14 days, placebo for 28 days, or benznidazole for 60 days. The study involves oral administration of these treatments in a parallel group design. The treatment period is followed by monitoring to evaluate the effects and parasite clearance over time. During the study, participants undergo PCR testing at months 2, 4, 6, and 12 to check for sustained parasitological clearance. Other assessments include monitoring adverse events, blood drug levels at various days during treatment, and serology tests at months 6 and 12. The study also tracks participant health for up to 48 months to observe long-term outcomes and safety. Total participation may last several years including treatment and follow-up.

Age: 18Years - 60YearsAll GendersPhase 2
22 locations
B

Actively Recruiting

Researchers are developing a registry of Brazilian patients with hereditary cardiovascular diseases by combining clinical information and genetic data. The study aims to identify which genes are most commonly affected and the frequency of these genetic changes within this population. The registry will help advance understanding and healthcare for hereditary heart conditions in Brazils public health system. Participants will be interviewed during their routine medical visits, and their DNA will be collected using buccal swabs for whole genome sequencing. This observational study does not involve any treatment but focuses on gathering detailed genetic and clinical data to better characterize hereditary cardiovascular diseases. The study is planned to run for 30 months starting from April 2025. During the study, participants will provide information through interviews and give DNA samples for sequencing. Researchers will measure diagnostic yield, genetic diversity, and variant frequency over the 30 months. The study does not involve additional interventions beyond data and sample collection, and participants will continue their usual medical care throughout the study period.

All AgesAll Genders
27 locations